Table 1.
Studies that analyse CD3+, CD4+, and CD8+ T cells by IHC and flow cytometry.
| Author | Method | N | Neo | Adj | Location | High CD3 yields | Statistics | High CD4 yields | Statistics | High CD8 yields | Statistics |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Brunner et al. (20) | IHC | 201 | 90* | NR | intra-tumoural | not sign. | UV (p = 0.317) | not sign. | UV (p = 0.713) | ||
| peri-tumourala | better OS | UV (p = 0.003) | better OS | UV (p = 0.002) | |||||||
| Katz et al. (16) | IHC TMA | 188 | 47* | 166 | intra-tumoural | not sign. | UV (p = 0.36) | better OS and DFS | MV (p = 0.02 & p = 0.04) | better OS | UV (p = 0.04) MV (p = 0.08) |
| Nakagawa et al. (21) | IHC | 162 | 65* | NR | intra-tumoural | not sign. | UV (p = 0.11) | not sign. | UV (p = 0.48) | ||
| peri-tumoural | not sign. | UV (p = 0.06) | not sign. | UV (p = 0.10) | |||||||
| Katz et al. (11) | IHC TMA | 162 | NR | NR | intra-tumoural | better DSS | MV (p = 0.04) | worse CSS | MV (p < 0.001) | better CSS | MV (p < 0.001) |
| Cavnar et al. (18) | IHC TMA | 156 | NR | NR | intra-tumoural | not sign. | UV (p = 0.9) | better OS and DFS | UV (p = 0.04 and p = 0.025) | not sign. | UV (p = 0.32) |
| Donadon et al. (13) | IHC | 121 | 96* | 64 | intra-tumoural | better OS | MV (p = 0.005) | ||||
| peri-tumoural | not sign. | UV (p = 0.458) | |||||||||
| Mlecnik et al. (15) | IHC | 114 | 80* | 77 | intra-tumoural | better OS | UV (p = 0.009) | Better OS and DFS | UV (p = < 0.001 and p = 0.004) | ||
| peri-tumoural | not sign. | UV (p = 0.23) | Better OS and DFS | UV (p = 0.02 and p = 0.027) | |||||||
| Tanis et al. (17) | IHC | 82 | 38* | 38 | intra-tumoural | not sign. | UV (NR) | not sign. | UV (NR) | not sign. | UV (NR) |
| peri-tumoural | better survival | UV (p = 0.031) | not sign. | UV (NR) | not sign. | UV (NR) | |||||
| Berthel et al. (12) | IHC | 36 | NR | NR | intra-tumoural | better OS | UV (p = 0.05) | better OS | UV (p = 0.05) | ||
| peri-tumoural | worse OS | UV (p = 0.05) | not sign. | UV (NR) | |||||||
| Pugh et al. (14) | Flow cy- | 11 | NR | NR | intra-tumoural | better OS | UV (p = 0.018) | ||||
| tometry | peri-tumouralb | not sign. | UV (p > 0.1) |
N, number of patients; Neo, neoadjuvant chemotherapy administered; Adj, adjuvant chemotherapy administered; NR, not reported; UV, univariable analysis; MV, multivariable analysis.
*
a certain percentage of patients in this study were administered to oxaliplatin-based neoadjuvant chemotherapeutic regimens.
a
“near stroma” was noted down as peri-tumoural.
b
“peri-tumoural liver” was noted down as peri-tumoural.